Pharma and Biotech


FTSE 100

  • Change Today:
  • 52 Week High: 2,263.00p
  • 52 Week Low: 1,637.40p
  • Currency: UK Pounds
  • Shares Issued: 4,067.35m
  • Volume: 794,563
  • Market Cap: £66,623m
  • RiskGrade: 129

GSK's MMR vaccine Priorix gets US FDA approval

By Michele Maatouk

Date: Monday 06 Jun 2022

LONDON (ShareCast) - (Sharecast News) - GlaxoSmithKline said on Monday that the US Food and Drug Administration has approved its Priorix vaccine for measles, mumps and rubella in people aged 12 months and older.
Priorix is currently licenced in more than 100 countries worldwide, including all European countries, Canada, Australia and New Zealand, with more than 800 million doses distributed to date.

Judy Stewart, senior vice president and head of US vaccines at GSK, said: "We're proud to make Priorix available in the US for the first time, adding a choice for providers to help protect patients against these highly-contagious diseases and to further strengthen offerings in our paediatric vaccine portfolio."

Temi Folaranmi, MD, vice president and vaccines therapeutic area head, US Medical Affairs, GSK, said: "Outbreaks of measles in recent years demonstrate how quickly diseases can return without widespread immunisation. Missed vaccinations during the pandemic makes children even more vulnerable to vaccine-preventable diseases like measles.

"Making Priorix available to patients in the US will ensure health care professionals have more than one option for this critical vaccine as they work to catch their patients up on recommended vaccinations."

Email this article to a friend

or share it with one of these popular networks:

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.


GSK Market Data

Currency UK Pounds
Share Price 1,638.00p
Change Today -21.40p
% Change -1.29 %
52 Week High 2,263.00p
52 Week Low 1,637.40p
Volume 794,563
Shares Issued 4,067.35m
Market Cap £66,623m
RiskGrade 129

GSK Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value Not Available
Price Trend
35.55% below the market average35.55% below the market average35.55% below the market average35.55% below the market average35.55% below the market average
37.50% above the sector average37.50% above the sector average37.50% above the sector average37.50% above the sector average37.50% above the sector average
Income Not Available
Growth Not Available

What The Brokers Say

Strong Buy 7
Buy 1
Neutral 13
Sell 0
Strong Sell 1
Total 22
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

GSK Dividends

  Latest Previous
  Q2 Q1
Ex-Div 18-Aug-22 19-May-22
Paid 06-Oct-22 01-Jul-22
Amount 16.25p 14.00p

Trades for 09-Aug-2022

Time Volume / Share Price
11:46 2 @ 1,638.00p
11:46 179 @ 1,638.20p
11:46 154 @ 1,638.00p
11:46 24 @ 1,638.00p
11:46 5 @ 1,638.00p

GSK Key Personnel

CEO Emma Walmsley
CFO Iain Mackay

Top of Page